Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...
New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment ...
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...
Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...
Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...
More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...